Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.
A Dutch province has awarded an unspecified sum to the Netherlands-based firms to combine their technologies for TCR and BCR repertoire sequencing and analysis.
Osang previously granted nonexclusive US distribution rights to the PCR-based test to SG Blocks and has a manufacturing arrangement for the test with Nexus Dx.
Amazon said that it will use its test for employees and other individuals who enter its facilities as part of its COVID-19 preparedness and response program.
Visby's single-use, fully integrated assay is designed to detect SARS-CoV-2 nucleic acid in samples collected either by a healthcare provider or self-collected.
Before launching its COVID-19 test, which generated most of Co-Diagnostics' revenues in 2020, the firm's sales primarily came from mosquito-borne virus testing.
For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million.
The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.
The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.
The automated sample-to-answer platform allows for a variety of assay types to be run simultaneously, such as molecular, immunochemistry, and cytometry tests.
The company is also working on a new Saphyr system that will have 14 times higher throughput than the current one, which can analyze 5,000 human genomes per year.
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
